Loading
Biocryst Pharmaceuticals Inc Stock: price and insider trades · United States
No insider purchase over the last 90 days. The latest was filed 31 May 2024.
Biocryst Pharmaceuticals Inc: what insiders have been doing
Every trade that managers of Biocryst Pharmaceuticals Inc disclose to SEC (Form 4) is tracked on this page. The company sits in the Healthcare & Pharma sector and is based in Durham, United States. It was founded in 1986. The last twelve months, up to 18 October 2026, brought 46 filings signed by 13 insiders.
There is no open-market purchase to report; the filings show 4 sales worth €1.1M by 3 insiders. The largest single trade was a sale of €509k by Barnes Alane P, published on 15 May 2026, equal to 0.023% of the market capitalisation.
Filings reach the SEC (Form 4) feed a median of 4 days after the trade. US insiders must file a Form 4 within two business days of a trade. Sales are harder to read than purchases, since they often meet personal needs such as tax or diversification.
Compared with its exchange (5,816 companies, median 19 filings), a count of 46 filings is above the norm. Looking back to 2016, when coverage begins, insiders filed 25 purchases and 17 sales. In its latest annual report filed with the SEC (10-K, fiscal year ended 31 December 2025), the company reported revenue of 874.8 m USD and net income of 263.9 m USD.
Elsewhere in the same sector, our signals recently picked up insider purchases at Cooper Companies, Inc. and Anixa Biosciences Inc. Source: insider filings from SEC (Form 4). Past trades are no guide to future returns.
Insider Decl.
262
Thresholds
n/a
Buy Volume
€1M
25 ops. · all time
Sell Volume
€2M
17 ops. · all time
Who traded when
BuySaleAlane P. Barnes2 sales
Machelle Sanders1 sale
Nancy J. Hutson1 sale
Theresa Heggie1 sale
Since the insiders bought
- +58.0%Entry US$6.79 · Close at T+365 US$10.73
- +63.6%Entry US$6.57 · Close at T+365 US$10.75
- +67.3%Entry US$6.33 · Close at T+365 US$10.59
Entry is the close on the day after publication, the first price a reader could act on. Prices in the listing currency. Past moves are not a forecast.
Analyst consensus: bullish or bearish?
Analysts rate Biocryst Pharmaceuticals Inc Buy (bullish), based on 11 analysts. Average price target: US$20.73.
This score ranks the purchase within its own market. A position size is suggested only on the venues of the backtested strategy universe; elsewhere, signals stay on watch. Not investment advice.
Fundamental score
Ranked 456 of 24,148 companies
84.2
score / 100
Value85
Quality84
FCF yld16%
Earn yld12%
EV/EBITDA7.5x
ROE·
Gross mgn98%
Net mgn30%
Debt/EBITDA1.3x
Pillars2/3
Transparent value + quality ranking, distinct from the insider signal.
Financial data
as of FY 2025FY ended December 2025 · cache
US$8.55
Analyst consensus
11 analystsBuy
US$11.00Target US$20.73(+142%)US$32.00
Income statement
RevenueUS$874.8M
Gross profitUS$855.8M98% margin
EBITDAUS$347.7M40% margin
Net incomeUS$263.9M-40.9% margin
Valuation
PER (forward)9.1x
Beta0.55
Balance sheet & cash
Market capUS$2.2B
Total debtUS$438.9M
Free Cash FlowUS$344.9M
Profitability & ownership
ROA52.9%
% insiders1.3%
% institutions105.3%
Last declaration on 15 June 2026
Declarations262 total
15,294 sharesCommon StockSEC:0000882796-26-000035:0
15,294 sharesCommon StockSEC:0000882796-26-000037:0
15,294 sharesCommon StockSEC:0000882796-26-000039:0
15,294 sharesCommon StockSEC:0000882796-26-000041:0
15,294 sharesCommon StockSEC:0000882796-26-000043:0
15,294 sharesCommon StockSEC:0000882796-26-000045:0
15,294 sharesCommon StockSEC:0000882796-26-000052:0
15,294 sharesCommon StockSEC:0000882796-26-000053:0
15,294 sharesCommon StockSEC:0000882796-26-000055:0
631 shares@ US$8.910.0002% mcap6.9% of flowCommon StockSEC:0000882796-26-000029:0
631 shares@ US$8.910.0002% mcap0.2% of flowCommon StockSEC:0000882796-26-000031:0
1,262 shares@ US$8.910.0004% mcap23.2% of flowCommon StockSEC:0000882796-26-000025:0
1,122 shares@ US$8.910.0004% mcap3.4% of flowCommon StockSEC:0000882796-26-000027:0
1,262 shares@ US$8.910.0004% mcap71.2% of flowCommon StockSEC:0000882796-26-000033:0
62,500 shares@ US$9.540.023% mcap22.9% of flowCommon StockSEC:0000882796-26-000021:1
62,500 shares@ US$5.040.012% mcap12.1% of flowCommon StockSEC:0000882796-26-000021:0
205,150 shares0Common StockSEC:0000882796-26-000019:0
49,933 shares@ US$10.110.020% mcap50.4% of flowCommon StockSEC:0000882796-26-000017:1
49,933 shares@ US$6.300.012% mcap31.4% of flowCommon StockSEC:0000882796-26-000017:0
150,000 shares@ US$5.5132.5% of flowCommon StockSEC:0000882796-26-000015:0
528 shares@ US$8.7528.8% of flowCommon StockSEC:0000882796-26-000013:0
421 shares@ US$8.750.1% of flowCommon StockSEC:0000882796-26-000011:0
1,285 shares@ US$8.7522.9% of flowCommon StockSEC:0000882796-26-000007:0
642 shares@ US$8.756.8% of flowCommon StockSEC:0000882796-26-000005:0
848 shares@ US$8.752.5% of flowCommon StockSEC:0000882796-26-000009:0
25 of 262 declarations
About Biocryst Pharmaceuticals Inc
BioCryst Pharmaceuticals, Inc. (ticker BCRX) is a U.S.-listed biotechnology company traded on NASDAQ in the United States, with a focused rare-disease strategy centered on hereditary angioedema (HAE) and selected adjacent programs. Founded in 1986 in Birmingham, Alabama, BioCryst later relocated its headquarters to Durham, North Carolina, where it is currently based. Over time, the company has evolved from a research-heavy biotech into a commercial-stage organization led by a core marketed product, while retaining a targeted pipeline of oral, small-molecule candidates.
The company’s commercial engine is ORLADEYO (berotralstat), an oral, once-daily prophylactic therapy for HAE attacks. ORLADEYO is BioCryst’s key revenue driver and the main strategic asset around which the business is organized. Management continues to expand the product’s addressable market through label and formulation expansion efforts, including pediatric access initiatives. Beyond its lead franchise, BioCryst also advances earlier-stage programs, notably BCX17725 for Netherton syndrome, alongside other preclinical and early clinical assets. The portfolio has been streamlined over time, with some legacy programs discontinued or de-emphasized, reflecting a more disciplined capital allocation framework.
Read moreShow less
From a competitive standpoint, BioCryst occupies a specialized but highly competitive HAE market, where patients and physicians can choose among multiple preventive or on-demand therapies. The company’s principal differentiator is convenience: an oral once-daily therapy can be attractive versus injectable alternatives, particularly in chronic prophylaxis. BioCryst also has an international footprint through commercial partnerships outside the United States, which extends ORLADEYO’s reach across multiple regions without requiring the company to build every market directly. Recent disclosures indicate solid commercial momentum, including strong 2025 ORLADEYO revenue growth and FDA acceptance of an NDA for ORLADEYO oral granules, a potential catalyst for pediatric expansion. BioCryst also announced the sale of its European ORLADEYO business, which suggests an ongoing portfolio optimization strategy and a sharper focus on the most value-accretive opportunities.
Recent ranked signals in the same sector
Purchases our model currently ranks for the recommendations list.
All recommendations
